Population pharmacokinetics of topiramate in Chinese children with epilepsy

被引:0
作者
Shifeng Wei
Xingmeng Li
Qiang Zhang
Han Wu
Yun Wu
Zhigang Zhao
Shenghui Mei
Weixing Feng
机构
[1] Capital Medical University,Department of Pharmacy, Beijing Tiantan Hospital
[2] Capital Medical University,Department of Clinical Pharmacology, College of Pharmaceutical Sciences
[3] Beijing Children’s Hospital,Department of Neurology
[4] Capital Medical University,undefined
来源
European Journal of Clinical Pharmacology | 2023年 / 79卷
关键词
Topiramate; Population pharmacokinetic model; Nonlinear mixed effects modeling; Chinese pediatric epilepsy patients; Body weight; Oxcarbazepine; Genetic polymorphism;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1401 / 1415
页数:14
相关论文
共 224 条
[1]  
Kanner AM(2022)Antiseizure medications for adults with epilepsy: a review JAMA 327 1269-1281
[2]  
Bicchi MM(2007)Topiramate: a review of its use in the treatment of epilepsy Drugs 67 2231-2256
[3]  
Lyseng-Williamson KA(2007)Novel anticonvulsant drugs Pharmacol Ther 113 165-183
[4]  
Yang LP(2013)Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling Eur J Pharm Sci 50 282-289
[5]  
Stefan H(2000)Clinical pharmacology of topiramate: a review Epilepsia 41 61-65
[6]  
Feuerstein TJ(2020)Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects Expert Opin Drug Metab Toxicol 16 227-238
[7]  
Jovanović M(2022)Simulations of topiramate dosage recommendations for poor compliance events Eur J Clin Pharmacol 78 1843-1850
[8]  
Sokić D(2006)Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 45 1061-1075
[9]  
Grabnar I(2008)Antiepileptic drugs–best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring ILAE Commission on Therapeutic Strategies Epilepsia 49 1239-1276
[10]  
Vovk T(2018)Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines Drug Des Devel Ther 12 271-280